Clinical course of hepatitis C virus‐positive patients with decompensated liver cirrhosis in the era of direct‐acting antiviral treatment

The aim of the present study was to investigate the clinical course in hepatitis C virus (HCV)‐positive patients with decompensated liver cirrhosis after direct‐acting antivirals (DAAs) have been used for HCV infection.

[1]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2019, Clinical Liver Disease.

[2]  K. Chayama,et al.  Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial , 2018, Journal of Gastroenterology.

[3]  M. Alavi,et al.  Inpatient hospital burden of hepatitis C‐diagnosed patients with decompensated cirrhosis , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[4]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[5]  M. Kudo,et al.  Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis , 2018, Liver Cancer.

[6]  M. Alavi,et al.  Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect‐acting antiviral era , 2017, Journal of viral hepatitis.

[7]  H. Toyoda,et al.  Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma , 2016, Journal of gastroenterology and hepatology.

[8]  K. Reddy,et al.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.

[9]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[11]  E. Gómez,et al.  The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages , 2014, Hepatology International.

[12]  G. D’Amico,et al.  Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients , 2014, Alimentary pharmacology & therapeutics.

[13]  P. Maisonneuve,et al.  Mortality Risk According to Different Clinical Characteristics of First Episode of Liver Decompensation in Cirrhotic Patients: A Nationwide, Prospective, 3-Year Follow-Up Study in Italy , 2013, The American Journal of Gastroenterology.

[14]  H. Moriwaki,et al.  Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  S. Waikar,et al.  Creatinine kinetics and the definition of acute kidney injury. , 2009, Journal of the American Society of Nephrology : JASN.

[16]  P. Hsu,et al.  Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding , 2008, Hepatology.

[17]  A. Sanyal,et al.  Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis , 2007, The American Journal of Gastroenterology.

[18]  M. Miquel,et al.  Probability of liver cancer and survival in HCV‐related or alcoholic‐decompensated cirrhosis. A study of 377 patients , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[19]  A. Muir,et al.  HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis , 2005, Hepatology.

[20]  R. Poupon,et al.  Improved survival after variceal bleeding in patients with cirrhosis over the past two decades , 2004, Hepatology.

[21]  R. Solá,et al.  Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. , 2004, Journal of hepatology.

[22]  E. Christensen,et al.  Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients , 2002, American Journal of Gastroenterology.

[23]  T M Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.

[24]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[25]  M. Navasa,et al.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.

[26]  T. Poynard,et al.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis , 1999, Hepatology.

[27]  M. Tong,et al.  The long‐term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states , 1999, Hepatology.

[28]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[29]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[30]  N. Hiramatsu,et al.  Guidelines for the Management of Hepatitis C Virus Infection , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[31]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[32]  R. Wiesner,et al.  Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.

[33]  J. Inadomi,et al.  Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. , 2000, Journal of hepatology.

[34]  R. W. Mccollum.  The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.